One group of investigators concluded, "While the prospects for maintaining viral suppression in people starting [antiretroviral therapy] remain good over the first 5 to 10 years, the longer-term prospects for continued viral suppression may increasingly depend on development of new antiretroviral drugs." They are right.
But we also need to increase prevention education and maintenance. In addition, strategies to conserve treatment options, including delaying HAART until the CD4+ cell count predicts an unacceptable risk of opportunistic infections and malignancy, selecting regimens that preserve recourse to active drugs in case of treatment failure, individualizing regimens to account for the convenience of patients and their susceptibility to certain side effects, use of therapeutic drug monitoring, and design of clinical trials to assess the level of virologic failure that must trigger a change in HAART, should be considered.
They got one thing right on SVU last night: Meth is death.